Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IDEATE
- Sponsors Bristol-Myers Squibb
- 16 Feb 2018 The trial has been completed in Italy according to European Clinical Trials Database record.
- 10 Jan 2018 The trial has been completed in Netherlands.
- 10 Dec 2017 The trial has been completed in Ireland (End date: 2017-08-22)